Clostridium perfringens epsilon prototoxin mutant rpETX Y30A/Y71A/H106P/Y196A as a vaccine candidate against enterotoxemia

Jige Du,Tuanjie Wang,Lei Xu,Cong Wang,Ying Liu,Chenfan Pan,Xiaoyun Chen,Zhen Zhu,Yufeng Luo,Chunsheng Yin
DOI: https://doi.org/10.1016/j.vaccine.2023.06.044
IF: 4.169
2023-06-25
Vaccine
Abstract:Epsilon toxin (ETX) is secreted by Clostridium perfringens ( C. perfringens ) as a relatively inactive prototoxin (pETX), which is enzymatically activated to ETX by removing carboxy-terminal and amino-terminal peptides. Genetically engineered ETX mutants have been shown to function as potential vaccine candidates in the prevention of the enterotoxemia caused by C. perfringens . In the present study, two recombinant site-directed mutants of pETX, rpETX Y30A/Y71A/H106P/Y196A (rpETX m41 ) and rpETX Y30A/H106P/Y196A/F199E (rpETX m42 ), were synthesized by mutating four essential amino acid residues (Tyr30, Tyr71, His106, Tyr196 or Phe199). Compared to recombinant pETX (rpETX), both rpETX m41 and rpETX m42 lacked the detectable toxicity in MDCK cells and mice, which suggested that both rpETX m41 and rpETX m42 are sufficiently safe to be vaccine candidates. Despite the fact that rpETX m41 and rpETX m42 were reactogenic with polyclonal antibodies against crude ETX, both single- and double-dose vaccination ( V s and V d , respectively) of rpETX m41 induced a higher level of IgG titer and protection in mice than that of rpETX m42 . Therefore, we selected rpETX m41 for the further study. Sheep received V s of 150 μg rpETX m41 developed significant levels of toxin-neutralizing antibodies persisting for at least 6 months, which conferred protection against crude ETX challenge without microscopic lesions. These data suggest that genetically detoxified rpETX Y30A/Y71A/H106P/Y196A could form the basis of a next-generation enterotoxemia vaccine.
immunology,medicine, research & experimental
What problem does this paper attempt to address?